Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for treating locally advanced or metastatic colorectal cancer
Status In progress
Process STA
ID number 1298

Provisional Schedule

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators 26 April 2018 - 25 May 2018

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
17 May 2018 The National Institute for Health and Care Excellence has been asked to conduct an appraisal of atezolizumab for treating locally advanced or metastatic colorectal cancer after 2 therapies We have recently invited stakeholders to respond to a written consultation on the draft scope for this topic. The company that market atezolizumab have shared confidential information with NICE, in light of this information NICE will not be progressing with the scoping exercise. Consequently the consultation on the draft scope will stop. If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar via email on
11 August 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance